Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | UBE2N | P61088 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14403228 | 0.87 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CSMN1; SMN2MAPT | |
| SCHEMBL6085911 | 0.86 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CCYP19A1MAPT | |
| SCHEMBL12900314 | 0.77 | FABP4 (0.50) | SMN1; SMN2MAPTLMNAHPGDUBE2N | |
| SCHEMBL6086279 | 0.75 | HTR6 (0.52) | SMN1; SMN2CYP19A1MAPTLMNAHTR6 | |
| SCHEMBL13852172 | 0.75 | PTGER4 (0.47) | ADRA2AADRA2BADRA2CMAPTTHRB | |
| SCHEMBL6191024 | 0.75 | SMN1; SMN2 (0.53) | SMN1; SMN2MAPTLMNAL3MBTL1APP | |
| SCHEMBL10019302 | 0.74 | KDM4E (0.47) | SMN1; SMN2MAPTLMNACNR2TP53 | |
| SCHEMBL11081014 | 0.74 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CCYP19A1SLC6A2 | |
| SCHEMBL15687280 | 0.74 | ALDH1A1 (0.38) | SMN1; SMN2MAPTTHRBLMNAL3MBTL1 | |
| SCHEMBL24622720 | 0.74 | ADRA2A (0.48) | ADRA2AADRA2BADRA2CP2RX7DBH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6987122-B2 | 2-(1H-indol-3-yl)-2-oxo-acetic acid amides with antitumor activity | NOVUSPHARMA S.P.A. (IT) | 2006-01-17 | — | — | US | disclosed |
| EP-1244652-B1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETAMIDES WITH ANTITUMOR ACTIVITY | CELL THERAPEUTICS EUROPE SRL (IT) | 2005-08-24 | — | — | EP | disclosed |
| US-6753342-B2 | ANTICARCINOGENIC AGENTS FOR LUNG AND COLON CANCER TREATMENT | NOVUSPHARMA S.P.A. (IT) | 2004-06-22 | — | — | US | disclosed |
| US-20040029858-A1 | 2-(1h-indol-3-yl)-2-oxo-acetic acid amides with antitumor activity | NOVUSPHARMA S.P.A. (IT) | 2004-02-12 | — | — | US | disclosed |
| US-20030158153-A1 | 2-(1h-indol-3-yl)-2-oxo-acetamides containing a thiophene or furan ring; anticarcinogenic agents particular against solid tumors of colon and lung | NOVUSPHARMA S.P.A. (IT) | 2003-08-21 | — | — | US | disclosed |
| EP-1322646-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETIC ACID AMIDES WITH ANTITUMOR ACTIVITY | Novuspharma S.p.A. (IT) | 2003-07-02 | — | — | EP | disclosed |
| EP-1244652-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETAMIDES WITH ANTITUMOR ACTIVITY | Cell Therapeutics Europe S.R.L. (IT) | 2002-10-02 | — | — | EP | disclosed |
| WO-2002008225-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETIC ACID AMIDES WITH ANTITUMOR ACTIVITY | NOVUSPHARMA S.P.A. (IT) | 2002-01-31 | — | — | WO | disclosed |
| WO-2001047916-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETAMIDES WITH ANTITUMOR ACTIVITY | NOVUSPHARMA S.P.A. (IT) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158153-A1 | 2-(1h-indol-3-yl)-2-oxo-acetamides containing a thiophene or furan ring; anticarcinogenic agents particular against solid tumors of colon and lung | IDO2, IDO1, TXNRD2 | ADRA2A 1008/4885ADRA2B 1965/4885ADRA2C 1243/4885 |
| US-20040029858-A1 | 2-(1h-indol-3-yl)-2-oxo-acetic acid amides with antitumor activity | IDO1, AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ADRA2A 112/4885ADRA2B 414/4885ADRA2C 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.